Lonza is expanding its capacities for the manufacture of medicinal products in Switzerland. According to a press release from the pharmaceutical supplier based in Basel, it is building a new aseptic filling and finishing line in Stein in the canton of Aargau to be completed by 2023. The new line will be able to fill ampoules, cartridges, and prefilled syringes for Lonza’s clients. It is intended for the processing of various medicinal products, including monoclonal antibodies, bioconjugates, and viral vectors. Lonza plans to use cutting-edge robots in Stein but still plans to create more than 70 jobs.
Additionally, Lonza plans to expand the capacity for its medicinal product services for parenteral administration routes at its site in the Stücki Park area in Basel by 2024. This above all focuses on products that are being used in early and late-phase clinical trials.
Peter Droc, Head of Drug Product Services at Lonza, states in the press release that Lonza’s offering of medicinal product services is world-class and that the Basel site forms a center of excellence in this respect within the globally active company. He adds: “Alongside the investment in the filling line in Stein, expanding the footprint and capabilities of our Drug Product Services allows us to answer customer demand for integrated solutions.”
